[go: up one dir, main page]

PE20050222A1 - TRIAZOLE COMPOUNDS AS VASOPRESSIN ANTAGONISTS - Google Patents

TRIAZOLE COMPOUNDS AS VASOPRESSIN ANTAGONISTS

Info

Publication number
PE20050222A1
PE20050222A1 PE2004000165A PE2004000165A PE20050222A1 PE 20050222 A1 PE20050222 A1 PE 20050222A1 PE 2004000165 A PE2004000165 A PE 2004000165A PE 2004000165 A PE2004000165 A PE 2004000165A PE 20050222 A1 PE20050222 A1 PE 20050222A1
Authority
PE
Peru
Prior art keywords
alkyl
tetraaza
benzo
chloro
ring
Prior art date
Application number
PE2004000165A
Other languages
Spanish (es)
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Alan Stobie
Thomas Ryckmans
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050222A1 publication Critical patent/PE20050222A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE TRIAZOL DE FORMULA (I), DONDE V ES -(CH2)d(O)e-, -CO-, O -CH(ALQUILOC1-C6); W ES -O-, -S(O)a- O -N(R1)-; R1 ES H, ALQUILO(C1-C6), (CH2)bCOR2, CO(CH2)bNR2R3, SO2R2, (CH2)cOR2, (CH2)cNR2R3 O (CH2)bhet1; het1 ES UN HETEROCICLO DE 3 A 8 ATOMOS QUE PUEDE CONTENER O, N O S, OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6); X E Y SON H, ALQUILO(C1-C6), HALOGENO, OH, CF3, OCF3, OR4; Z ES -(CH2)f(O)g-, -CO-, O -CH(ALQUILO(C1-C6))-; EL ANILLO A ES UN HETEROCICLO SATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDO CON OH Y AL MENOS UN N DEL ANILLO PUEDE ESTAR SUSTITUIDO CON O; EL ANILLO B ES UN FENILO O UN HETEROCICLO INSATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, CN, CONH2, CF3, OCF3, Y AL MENOS UN N PUEDE ESTAR SUSTITUIDO CON O. SON COMPUESTOS PREFERIDOS: TRICLOROHIDRATO DE 8-CLORO-5-METIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, 8-CLORO-5-METANOSULFONIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']-BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, DIMETILAMINO DEL ACIDO 8-CLORO-1-(1-PIRIMIDIN-2-IL-PIPERIDIN-4-IL)-4H,6H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO-5-SULFONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y COMPUESTOS INTERMEDIOS. UNA FORMULACION FARMACEUTICA QUE LOS CONTIENE. ESTOS COMPUESTOS MUESTRAN UNA ACTIVIDAD ANTAGONISTA DE VASOPRESINA Y PUEDEN USARSE EN EL TRATAMIENTO DE DISMENORREAREFERS TO TRIAZOLE DERIVATIVES OF FORMULA (I), WHERE V IS - (CH2) d (O) e-, -CO-, O -CH (ALKYLOC1-C6); W IS -O-, -S (O) a- O -N (R1) -; R1 IS H, (C1-C6) ALKYL, (CH2) bCOR2, CO (CH2) bNR2R3, SO2R2, (CH2) cOR2, (CH2) cNR2R3 O (CH2) bhet1; het1 IS A HETEROCYCLE OF 3 TO 8 ATOMS THAT MAY CONTAIN O, N OR S, OPTIONALLY SUBSTITUTED WITH ALKYL (C1-C6); X AND Y ARE H, (C1-C6) ALKYL, HALOGEN, OH, CF3, OCF3, OR4; Z IS - (CH2) f (O) g-, -CO-, O -CH ((C1-C6) ALKYL) -; THE RING A IS A SATURATED HETEROCYCLE CONTAINING N, FROM 4 TO 7 MEMBERS OPTIONALLY SUBSTITUTED WITH OH AND AT LEAST ONE N OF THE RING MAY BE SUBSTITUTED WITH O; RING B IS AN INSATURATED PHENYL OR HETEROCYCLE CONTAINING N, FROM 4 TO 7 MEMBERS, OPTIONALLY SUBSTITUTED WITH OH, HALOGEN, CN, CONH2, CF3, OCF3, AND AT LEAST ONE N MAY BE SUBSTITUTED WITH O. PREFERRED COMPOUNDS ARE: 8-CHLORO-5-METHYL-1- (3,4,5,6-TETRAHYDRO-2H- [1,2 '] BIPYRIDINYL-4-IL) -5,6-DIHYDRO-4H-2,3 TRICHLOROHYDRATE, 5,10b-TETRAAZA-BENZO [e] BLUE, 8-CHLORO-5-METHANOSULPHONYL-1- (3,4,5,6-TETRAHYDRO-2H- [1,2 '] - BIPYRIDINYL-4-IL) -5 , 6-DIHYDRO-4H-2,3,5,10b-TETRAAZA-BENZO [e] AZULENE, 8-CHLORO-1- (1-PYRIMIDIN-2-IL-PIPERIDIN-4-IL) -4H ACID DIMETHYLAMINE, 6H-2,3,5,10b-TETRAAZA-BENZO [e] AZULENO-5-SULFONICO, AMONG OTHERS. ALSO REFERS TO A PROCEDURE OF PREPARATION AND INTERMEDIATE COMPOUNDS. A PHARMACEUTICAL FORMULATION THAT CONTAINS THEM. THESE COMPOUNDS SHOW ANTAGONIST ACTIVITY OF VASOPRESSIN AND MAY BE USED IN THE TREATMENT OF DYSMENORRHEA

PE2004000165A 2003-02-19 2004-02-17 TRIAZOLE COMPOUNDS AS VASOPRESSIN ANTAGONISTS PE20050222A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
PE20050222A1 true PE20050222A1 (en) 2005-04-13

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000165A PE20050222A1 (en) 2003-02-19 2004-02-17 TRIAZOLE COMPOUNDS AS VASOPRESSIN ANTAGONISTS

Country Status (11)

Country Link
CN (1) CN1751047A (en)
AR (1) AR043210A1 (en)
CL (1) CL2004000293A1 (en)
GB (1) GB0303852D0 (en)
GT (1) GT200400020A (en)
NL (1) NL1025527C2 (en)
PA (1) PA8596101A1 (en)
PE (1) PE20050222A1 (en)
TW (1) TW200500367A (en)
UY (1) UY28201A1 (en)
WO (1) WO2004074291A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (en) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclic benzazepine derivatives and their use
MX2007002248A (en) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepines and their use as vasopressin antagonists.
WO2006114706A1 (en) * 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
HRP20121060T1 (en) 2008-11-13 2013-01-31 F. Hoffmann - La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
PE20110590A1 (en) * 2008-11-18 2011-08-31 Hoffmann La Roche DIHYDROTETRAAZABENZOAZULENES ALKYL CYCLES
MY150837A (en) 2008-11-28 2014-02-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
CA2779088A1 (en) * 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
UY33650A (en) 2010-10-07 2012-04-30 Takeda Pharmaceutical HETEROCYCLIC COMPOUNDS
RU2011122942A (en) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" NEW KINAZ INHIBITORS
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
CN103842365B (en) * 2011-10-05 2017-06-23 霍夫曼-拉罗奇有限公司 As the triazine of 5 oxa- of cyclohexyl 4H, 6H 2,3,10b simultaneously [e] Azulene of V1a antagonists
CN104364239B (en) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 Diaza spiro cycloalkane and azaspiro alkane
CN102766674A (en) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 Establishment of screening platform for cynomolgus monkey antidiuretic hormone receptor V1A antagonist
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
CN105492010B (en) 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 V1a antagonists for the treatment of phase shift sleep disorders
PE20160845A1 (en) 2013-11-26 2016-09-10 Hoffmann La Roche NEW OCTAHYDRO-CYCLOBUTE [1,2-C; 3,4-C '] DIPIRROL-2-ILO
MY175464A (en) 2013-12-05 2020-06-29 Hoffmann La Roche Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
HUE046820T2 (en) 2014-03-26 2020-03-30 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA032357B1 (en) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
MX377277B (en) 2015-09-04 2025-03-07 Hoffmann La Roche PHENOXYMETHYL DERIVATIVES.
RU2725138C2 (en) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг New bicyclic compounds as double inhibitors of autotaxin (atx)/carbonic anhydrase (ca)
BR112018006034A2 (en) 2015-09-24 2018-10-09 Hoffmann La Roche bicyclic compounds as atx inhibitors
MA42923A (en) 2015-09-24 2021-04-28 Hoffmann La Roche BICYCLIC COMPOUNDS AS MIXED ATX / CA INHIBITORS
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
KR20190129924A (en) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 Heterocyclic Compounds Useful as Dual Autotaxin (ATX) / Carbon Anhydrase (CA) Inhibitors
CN110382484B (en) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 New bicyclic compounds as ATX inhibitors
US11186577B2 (en) * 2017-06-05 2021-11-30 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HU231206B1 (en) * 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines
CN111170983B (en) * 2019-12-26 2021-07-09 中国农业大学 A kind of benzylthioacetamide compound and its preparation method and application
CN114644635B (en) * 2020-12-21 2023-02-03 上海济煜医药科技有限公司 Triazole tricyclic derivatives, preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
BR9713253A (en) * 1996-11-01 1999-11-03 American Home Prod 3-carboxamide derivatives of 5h-pyrrole [2,1-c] [1,4] -benzodiazepines
PT1147115E (en) * 1999-01-19 2004-02-27 Ortho Mcneil Pharm Inc TRICYCLE BENZODIAZEPINS AS VASOPRESSIN RECEPTOR ANTAGONISTS
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
CL2004000293A1 (en) 2005-01-07
PA8596101A1 (en) 2005-08-04
AR043210A1 (en) 2005-07-20
UY28201A1 (en) 2004-09-30
TW200500367A (en) 2005-01-01
CN1751047A (en) 2006-03-22
GT200400020A (en) 2004-09-21
GB0303852D0 (en) 2003-03-26
WO2004074291A1 (en) 2004-09-02
NL1025527A1 (en) 2004-08-23
NL1025527C2 (en) 2005-03-14

Similar Documents

Publication Publication Date Title
PE20050222A1 (en) TRIAZOLE COMPOUNDS AS VASOPRESSIN ANTAGONISTS
ES2125377T3 (en) N-ACILATED TRICYCLIC AZAHETEROCICLICOS USEFUL AS VASOPRESSIN ANTAGONISTS.
AR022230A1 (en) TRIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND USE OF THE SAME TO PREPARE SUCH COMPOSITION
AP1965A (en) Tropane derivatives useful in therapy.
EA200201179A1 (en) DERIVATIVES 2-AMINOKARBONIL-9H-PURINA
EA200400054A1 (en) SUBSTITUTED NAFTILINDOL DERIVATIVES AS AN INHIBITORS INHIBITOR INHIBITOR PLASMINOGEN TYPE 1 (PAI-1) INHIBITOR
UY27109A1 (en) DERIVATIVES OF QUINAZOLONA AS ANTAGONISTS OF ADRENERGIC RECEPTORS ALFA-1A / B
SV1999000016A (en) DERIVATIVES OF 2- (PURIN-9-IL-TETRAHIDROFURAN-3,4-DIOL REF. PG3443 / SV
ATE365740T1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES
PE20070018A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES
DK1546134T3 (en) Piperazine-substituted arylbenzodiazepines
PE20080706A1 (en) ARYLMIDAZOLONES AND ARYLTHRIAZOLONES SUBSTITUTED AS VASOPPRESSIN RECEPTOR INHIBITORS
NZ509321A (en) Use of an estrogen agonist/antagonist to treat conditions responsive to estrogen such as rheumatoid arthritis, colon cancer, tissue wounds and cataracts
PA8547901A1 (en) 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY
EA200301306A1 (en) DERIVATIVES 1-PHENYLSULFONIL-1,3-DIHYDRO-2H-INDOL-2-SHE, THEIR PRODUCTION AND THEIR THERAPEUTIC APPLICATION
PE20020179A1 (en) DERIVATIVES OF (6S, 9R, 10S, 11S, 13S, 16R, 17R) -9-CHLORO-6-FLUORO-11-HYDROXY-10,13,16-TRIMETHYL-3-OXO-6,7,8,9, 10,11,12,13,14,15,16,17-DODECAHYDRO-3H-CYCLOPENTA [a] CARBOXYL PHENANTHRENE
MXPA05011710A (en) Fused pyrimidine derivatives with crf activity.
BR0317294A (en) Compound, pharmaceutical formulation, use of a compound, methods for prevention and / or treatment of conditions associated with glycogen synthase kinase-3 and disease prevention and / or treatment, and use of intermediates
ATE416767T1 (en) 5-HALO-TRPYTAMIN DERIVATIVES AS 5-HT6 AND/OR 5-HT7 RECEPTOR LIGANDS
PA8495101A1 (en) DERIVATIVES OF 13-METHYLERITROMYCIN
DE60024414D1 (en) OXADIAZOL COMPOUNDS AND COMPOSITIONS FOR THE DISPOSAL OF ACTIVE SUBSTANCES
TR200002380T2 (en) New triazolo (4,5-d) pyrimidine compounds
ATE302203T1 (en) PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
AR035452A1 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTIARRITHMIC COMPOUNDS, PROCEDURE FOR THE PREPARATION OF THESE SALTS, PHARMACEUTICAL FORMULATION AND THE USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF MEDICINES FOR USE IN THE PROPHYLAXIS OR TREATMENT OF ARRITMIA
TR200101711T2 (en) Antihistamine spiro compounds.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed